Phone: 614/488-2118
Fax: 614/488-2647

1335 Dublin Rd., Suite 124A
Columbus, OH 43215

Protocol Categories

View All Protocols


Multiple Disease Sites

Alliance A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Alliance A211901
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
ECOG EAY131 MASTER
Molecular Analysis for Therapy Choice (MATCH)
ECOG EAY131 Subprotocol H
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid, Colorectal, Adenocarcinoma, and Non-Small Cell Lung Cancer)
ECOG EAY131 Subprotocol Z1M
MATCH Treatment Subprotocol Z1M: EAY131-Z1M: Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy.
SWOG S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors